{"id":"ixabepilone-ixempra","safety":{"commonSideEffects":[{"rate":"60-70","effect":"Peripheral neuropathy"},{"rate":"25-30","effect":"Neutropenia"},{"rate":"40-50","effect":"Fatigue"},{"rate":"10-15","effect":"Myalgia/arthralgia"},{"rate":"30-40","effect":"Nausea"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-20","effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1201752","moleculeType":"Small molecule","molecularWeight":"506.71"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ixabepilone is a microtubule-stabilizing agent that binds to β-tubulin and promotes microtubule assembly while inhibiting depolymerization. This leads to cell cycle arrest in the G2/M phase and triggers apoptosis in cancer cells. Unlike taxanes, ixabepilone can overcome certain resistance mechanisms and remains effective against some taxane-resistant tumors.","oneSentence":"Ixabepilone stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:32.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy)"},{"name":"Taxane-resistant breast cancer"}]},"trialDetails":[{"nctId":"NCT01375829","phase":"PHASE1","title":"Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-27","conditions":"Adult Solid Neoplasm","enrollment":22},{"nctId":"NCT04796324","phase":"PHASE2","title":"Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.","status":"TERMINATED","sponsor":"Allarity Therapeutics","startDate":"2021-03-01","conditions":"Metastatic Breast Cancer","enrollment":13},{"nctId":"NCT00877500","phase":"PHASE2","title":"Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-30","conditions":"Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma","enrollment":116},{"nctId":"NCT00977574","phase":"PHASE2","title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma","enrollment":349},{"nctId":"NCT01349088","phase":"PHASE1, PHASE2","title":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-12","conditions":"Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":""},{"nctId":"NCT03393741","phase":"","title":"Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-29","conditions":"Breast Cancer, Breast Neoplasms","enrollment":5},{"nctId":"NCT03093155","phase":"PHASE2","title":"Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab","status":"COMPLETED","sponsor":"Yale University","startDate":"2017-04-03","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":78},{"nctId":"NCT00020371","phase":"PHASE1","title":"BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-09","conditions":"Unspecified Adult Solid Tumor, Protocol Specific, Neutropenia","enrollment":""},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":"Breast Cancer","enrollment":762},{"nctId":"NCT00765765","phase":"PHASE1, PHASE2","title":"Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2009-02","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT00879086","phase":"PHASE2","title":"A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-03-31","conditions":"Breast Cancer","enrollment":104},{"nctId":"NCT02915744","phase":"PHASE3","title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-11","conditions":"Metastasis, Breast Cancer","enrollment":178},{"nctId":"NCT02067416","phase":"PHASE2","title":"PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer","status":"WITHDRAWN","sponsor":"Jenny C. Chang, MD","startDate":"2012-07","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT01446016","phase":"PHASE2","title":"Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2011-09","conditions":"Breast Neoplasms, Breast Cancer","enrollment":38},{"nctId":"NCT00785291","phase":"PHASE3","title":"Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-10-13","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":799},{"nctId":"NCT00828308","phase":"PHASE2","title":"Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer","status":"COMPLETED","sponsor":"Brown University","startDate":"2009-02","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT00741988","phase":"PHASE2","title":"Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-09","conditions":"Non-Small Cell Lung Cancer","enrollment":82},{"nctId":"NCT00866905","phase":"PHASE2","title":"Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-04","conditions":"Breast Cancer","enrollment":168},{"nctId":"NCT01097642","phase":"PHASE2","title":"Neo-Adjuvant Study in Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2008-10-10","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT01492101","phase":"PHASE3","title":"The BEACON Study (Breast Cancer Outcomes With NKTR-102)","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2011-12","conditions":"Locally Recurrent Breast Cancer, Metastatic Breast Cancer","enrollment":852},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00162136","phase":"PHASE1","title":"Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2005-09","conditions":"Solid Malignancies","enrollment":35},{"nctId":"NCT00082433","phase":"PHASE3","title":"Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2003-11","conditions":"Cancer, Breast Cancer","enrollment":1221},{"nctId":"NCT00080301","phase":"PHASE3","title":"Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2003-09","conditions":"Breast Cancer, Metastases","enrollment":752},{"nctId":"NCT00207090","phase":"PHASE1","title":"Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2005-09","conditions":"Advanced Solid Tumors, Neoplasms","enrollment":19},{"nctId":"NCT00723957","phase":"PHASE2","title":"A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-12","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer","enrollment":260},{"nctId":"NCT00983801","phase":"PHASE2","title":"Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2009-11","conditions":"Stomach Neoplasms","enrollment":58},{"nctId":"NCT00832117","phase":"PHASE1","title":"Phase I Combination Ixabepilone + Cisplatin","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2009-05","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT01079793","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2010-05-26","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01818999","phase":"PHASE2","title":"Ixabepilone and SBRT For Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-08","conditions":"METASTATIC BREAST CANCER","enrollment":""},{"nctId":"NCT00717704","phase":"PHASE1","title":"Solid Tumors Using Ixabepilone and Dasatinib","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2008-07","conditions":"Solid Tumor","enrollment":19},{"nctId":"NCT00924066","phase":"PHASE2","title":"Ixabepilone to Treat Cervical Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-11","conditions":"Cervical Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma","enrollment":41},{"nctId":"NCT01084057","phase":"PHASE1","title":"Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2010-05-17","conditions":"Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":56},{"nctId":"NCT01416389","phase":"PHASE2","title":"A Study of LY2523355 in Participants With Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-08","conditions":"Metastatic Breast Cancer","enrollment":39},{"nctId":"NCT01168232","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-07","conditions":"Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma","enrollment":42},{"nctId":"NCT01220609","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma","enrollment":26},{"nctId":"NCT00095979","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-05","conditions":"Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma","enrollment":52},{"nctId":"NCT00025155","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-07","conditions":"Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer","enrollment":51},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT00096317","phase":"PHASE1","title":"Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2003-03","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":29},{"nctId":"NCT00672009","phase":"PHASE2","title":"A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2008-04","conditions":"Prostatic Diseases, Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":11},{"nctId":"NCT00005807","phase":"PHASE1","title":"Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2000-07","conditions":"Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":40},{"nctId":"NCT00030706","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2004-11","conditions":"Ovarian Cancer, Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00627978","phase":"PHASE2","title":"Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-11","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT00923130","phase":"PHASE2","title":"Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01-07","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT01012362","phase":"PHASE1","title":"Study of Pazopanib and Ixabepilone in Patients With Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-12","conditions":"Breast Cancer, Lung Cancer, Colon Cancer","enrollment":31},{"nctId":"NCT00331344","phase":"PHASE1, PHASE2","title":"Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":100},{"nctId":"NCT00045708","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma","enrollment":57},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00789581","phase":"PHASE3","title":"A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2008-12","conditions":"Breast Cancer","enrollment":614},{"nctId":"NCT00637897","phase":"PHASE1","title":"Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-03","conditions":"Breast Cancer","enrollment":24},{"nctId":"NCT00883116","phase":"PHASE3","title":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2009-08","conditions":"Endometrial Cancer","enrollment":551},{"nctId":"NCT00058084","phase":"PHASE2","title":"Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-03","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":80},{"nctId":"NCT00207129","phase":"PHASE1","title":"Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2004-10","conditions":"Advanced Solid Tumors, Neoplasms","enrollment":25},{"nctId":"NCT01018966","phase":"PHASE1","title":"Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2004-04","conditions":"Solid Tumors","enrollment":25},{"nctId":"NCT00004927","phase":"PHASE1","title":"BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"R-Pharm","startDate":"1999-07","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01019577","phase":"PHASE2","title":"Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2005-10","conditions":"Metastatic Breast Cancer","enrollment":54},{"nctId":"NCT01027208","phase":"PHASE2","title":"A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2006-12","conditions":"Metastatic Breast Cancer","enrollment":20},{"nctId":"NCT00049244","phase":"PHASE1","title":"BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2002-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00080262","phase":"PHASE2","title":"Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2004-02","conditions":"Breast Cancer, Metastases","enrollment":125},{"nctId":"NCT00309049","phase":"PHASE1, PHASE2","title":"Ixabepilone Administered as an Enteric Coated Formulation.","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2006-04","conditions":"Cancer","enrollment":30},{"nctId":"NCT01075100","phase":"PHASE2","title":"Ixabepilone + Carboplatin Metastatic Breast Cancer","status":"COMPLETED","sponsor":"US Oncology Research","startDate":"2010-01","conditions":"Metastatic Breast Cancer","enrollment":103},{"nctId":"NCT00362830","phase":"PHASE1","title":"A Study of the Alternative Administration of Ixabepilone and Vinflunine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-08","conditions":"Cancer","enrollment":60},{"nctId":"NCT00593827","phase":"PHASE2","title":"Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-05","conditions":"Metastatic Breast Cancer","enrollment":176},{"nctId":"NCT00568022","phase":"PHASE1","title":"A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-02","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT00634088","phase":"PHASE1","title":"Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":13},{"nctId":"NCT00422097","phase":"PHASE1","title":"A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2007-01","conditions":"Cancer","enrollment":40},{"nctId":"NCT00322374","phase":"PHASE1","title":"Phase I Combination w/ Epirubicin","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2006-08","conditions":"Metastatic Breast Cancer","enrollment":42},{"nctId":"NCT00490646","phase":"PHASE2","title":"A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-02","conditions":"Metastatic Breast Cancer","enrollment":50},{"nctId":"NCT00370552","phase":"PHASE2","title":"A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2007-03","conditions":"Metastatic Breast Cancer","enrollment":136},{"nctId":"NCT00633464","phase":"PHASE2","title":"Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer","enrollment":79},{"nctId":"NCT00383149","phase":"PHASE2","title":"A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2007-01","conditions":"Metastatic Pancreatic Cancer","enrollment":58},{"nctId":"NCT00632424","phase":"PHASE1","title":"Phase 1 Trial of Oral Ixabepilone","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-05","conditions":"Advanced Solid Tumors","enrollment":23},{"nctId":"NCT00182767","phase":"PHASE1, PHASE2","title":"Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-01","conditions":"Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer","enrollment":45},{"nctId":"NCT00546364","phase":"PHASE2","title":"Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-02","conditions":"Breast Neoplasms","enrollment":62},{"nctId":"NCT00683904","phase":"PHASE1","title":"Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":12},{"nctId":"NCT00455533","phase":"PHASE2","title":"Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-10","conditions":"Breast Cancer","enrollment":384},{"nctId":"NCT00035516","phase":"PHASE2","title":"A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2001-02","conditions":"Carcinoma, Non-small-cell Lung","enrollment":""},{"nctId":"NCT00998738","phase":"PHASE3","title":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2009-11","conditions":"Neuropathy, Pain, Recurrent Breast Carcinoma","enrollment":1},{"nctId":"NCT00884676","phase":"PHASE1","title":"Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors","status":"COMPLETED","sponsor":"Jaime Merchan","startDate":"2008-11","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":36},{"nctId":"NCT01057212","phase":"PHASE2","title":"Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Providence Health & Services","startDate":"2010-02","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT00798252","phase":"PHASE1","title":"Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03","conditions":"Advanced Cancer","enrollment":111},{"nctId":"NCT00022542","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-06","conditions":"Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma","enrollment":26},{"nctId":"NCT00049400","phase":"PHASE1","title":"S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2003-10","conditions":"Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":78},{"nctId":"NCT00821886","phase":"PHASE2","title":"Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-02","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT00825734","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2009-03","conditions":"Metastatic Breast Cancer","enrollment":83},{"nctId":"NCT00751868","phase":"PHASE2","title":"FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2008-09","conditions":"Breast Cancer","enrollment":47},{"nctId":"NCT00331643","phase":"PHASE2","title":"Ixabepilone in Treating Young Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04","conditions":"Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Alveolar Childhood Rhabdomyosarcoma","enrollment":120},{"nctId":"NCT00924352","phase":"PHASE1, PHASE2","title":"Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Accelerated Community Oncology Research Network","startDate":"2009-06","conditions":"Metastatic Breast Cancer","enrollment":56},{"nctId":"NCT00079326","phase":"PHASE2","title":"Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01","conditions":"HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer","enrollment":39},{"nctId":"NCT00058019","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-02","conditions":"Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":51},{"nctId":"NCT01170871","phase":"PHASE1","title":"Ixabepilone and Pemetrexed/Solid Tumors","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"","conditions":"Advanced Solid Tumors","enrollment":""},{"nctId":"NCT00077376","phase":"PHASE2","title":"Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-03","conditions":"HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer","enrollment":61},{"nctId":"NCT00023946","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Liver or Gallbladder Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-08","conditions":"Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer","enrollment":50},{"nctId":"NCT00087139","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":124},{"nctId":"NCT00022477","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2001-09","conditions":"Colorectal Cancer","enrollment":24},{"nctId":"NCT00033306","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2002-02","conditions":"Colorectal Cancer","enrollment":2},{"nctId":"NCT00016965","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-07","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT00070096","phase":"PHASE2","title":"Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-08","conditions":"Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":29},{"nctId":"NCT00016393","phase":"PHASE2","title":"BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-06","conditions":"Prostate Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ixempra","azaepothilone B","BMS-247550"],"phase":"phase_3","status":"active","brandName":"Ixabepilone (Ixempra)","genericName":"Ixabepilone (Ixempra)","companyName":"SCRI Development Innovations, LLC","companyId":"scri-development-innovations-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ixabepilone stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division. Used for Metastatic or locally advanced breast cancer (in combination with capecitabine or as monotherapy), Taxane-resistant breast cancer.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-12-31T00:00:00.000Z","mah":"Bristol-Myers Squibb Pharma EEIG","brand_name_local":"Ixempra","application_number":"EMEA/H/C/000930"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}